Go Pro
NASDAQ:FEMY

Femasys Q2 2024 Earnings Report

Femasys logo
$2.66 -0.29 (-9.83%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$2.65 -0.01 (-0.26%)
As of 08/7/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Femasys EPS Results

Actual EPS
-$4.20
Consensus EPS
-$3.60
Beat/Miss
Missed by -$0.60
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
$0.22 million
Expected Revenue
$0.50 million
Beat/Miss
Missed by -$280.00 thousand
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Femasys' Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Femasys Earnings Headlines

What Elon told his top shareholders in Texas
Late last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double America's energy output without building a single new power plant. The plan centers on a little-known Tesla-incubated venture already generating over 12 billion dollars a year and growing 168 percent annually. Musk says it could grow faster than Tesla's car business. A public reveal is expected on October 21, before wider attention catches on.tc pixel
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY) International, Inc. is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography. This system is intended to facilitate earlier and more accurate diagnosis of intrauterine abnormalities such as polyps, fibroids and adhesions. Femasys is also developing a pipeline of complementary devices aimed at expanding its portfolio of interventional gynecological tools.

Femasys is listed on the Nasdaq under the ticker symbol FEMY and is incorporated in Delaware with principal executive offices in Beijing, China. The company’s leadership team includes medical device veterans with deep experience in product development, regulatory affairs and commercial strategy. Femasys continues to pursue regulatory clearances in key markets, including CE marking in Europe, while exploring opportunities to introduce its technologies across Asia, North America and other regions.

View Femasys Profile